Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capmatinib Hydrochloride

FDA-approved product (tablet, oral), marketed as Tabrecta.

Registered studies
3
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Capmatinib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capmatinib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-10.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capmatinib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

    NCT03192501 · start 2017-07-01

    Registered record
    Registry ID
    NCT03192501
    Conditions
    Lung Cancer; Gene Abnormality; Gene Product Sequence Variation; Cancer
    Interventions
    inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2017-07-01
    Completion
    2039-07-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Gene Abnormality; Gene Product Sequence Variation; Cancer
    Interventioninhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
    PhaseNot recorded
    Registry statusRecruiting

  • A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

    NCT02468661 · start 2015-09-23

    Registered record
    Registry ID
    NCT02468661
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    INC280 single agent; erlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2015-09-23
    Completion
    2018-12-05
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionINC280 single agent; erlotinib
    PhasePhase 1
    Registry statusTerminated

  • INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

    NCT01911507 · start 2013-08-27

    Registered record
    Registry ID
    NCT01911507
    Conditions
    Recurrent Non-small Cell Lung Cancer
    Interventions
    INC280; erlotinib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08-27
    Completion
    2020-08-26
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Non-small Cell Lung Cancer
    InterventionINC280; erlotinib hydrochloride
    PhasePhase 1
    Registry statusCompleted